Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2012. The report serves to notify the SEC of the publication of a Base Prospectus dated September 5, 2012, which was approved by the UK Listing Authority.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the announcement of a new debt issuance program rather than reporting operational financial results.
Material Changes
The primary material event disclosed is the establishment of a £15,000,000,000 Euro Medium Term Note Programme involving GlaxoSmithKline plc, GlaxoSmithKline Capital plc, and GlaxoSmithKline Capital Inc. No comparative financial changes versus prior periods are detailed in this specific filing.
Outlook, Risks, and Contingencies
The filing includes a standard disclaimer regarding the Base Prospectus, noting that the information is targeted at residents of specific countries and should not be relied upon by persons outside those jurisdictions. Investors are advised to ascertain their eligibility as intended addressees before relying on the prospectus information. No specific management commentary on future business outlook or operational risks is included in this text.
Investor Verification Checklist
- Verify the full terms of the £15 billion Euro Medium Term Note Programme in the Base Prospectus.
- Confirm eligibility to access the Base Prospectus based on country of residence as specified in the document.
- Review the Base Prospectus available via the National Storage Mechanism at www.Hemscott.com/nsm.do for detailed risk factors.
- Note that this filing does not contain quarterly or annual financial performance data.